Summary
Stryker Corporation reported a solid first quarter for 2022, with net sales increasing by 8.1% to $4.275 billion, driven by broad-based growth across its MedSurg and Neurotechnology and Orthopaedics and Spine segments. This growth was primarily fueled by increased unit volume, although partially offset by a slight decrease in prices and negatively impacted by foreign currency exchange rates. The company successfully completed a significant acquisition of Vocera Communications for $2.6 billion, which is expected to enhance its digital capabilities and expand its presence in adjacent markets. Operationally, while gross profit margin saw a slight increase, the company faced inflationary pressures impacting costs. Research and development expenses saw a significant jump, reflecting strategic investments in new technologies and product development. Net earnings increased to $323 million, or $0.84 per diluted share. Despite the operational cost pressures and the large acquisition, Stryker's financial position remains strong, with robust liquidity and a solid investment-grade credit rating, positioning it well to navigate ongoing market dynamics.
Financial Highlights
50 data points| Revenue | $4.28B |
| Cost of Revenue | $1.54B |
| Gross Profit | $2.73B |
| R&D Expenses | $413.00M |
| SG&A Expenses | $1.71B |
| Operating Expenses | $2.29B |
| Operating Income | $447.00M |
| Net Income | $323.00M |
| EPS (Basic) | $0.86 |
| EPS (Diluted) | $0.84 |
| Shares Outstanding (Basic) | 377.70M |
| Shares Outstanding (Diluted) | 382.70M |
Key Highlights
- 1Net sales grew 8.1% to $4.275 billion, with constant currency growth of 9.9%, indicating strong underlying demand.
- 2The company completed the acquisition of Vocera Communications for $2.6 billion, a strategic move to bolster its digital health offerings.
- 3MedSurg and Neurotechnology segment sales increased by 10.6% (12.1% in constant currency), and Orthopaedics and Spine segment sales grew by 5.1% (7.2% in constant currency).
- 4Research, Development, and Engineering (R&D&E) expenses surged by 43.4% to $413 million, reflecting increased investment in innovation and new product development.
- 5Net earnings increased to $323 million, or $0.84 per diluted share, compared to $302 million, or $0.79 per diluted share, in the prior year.
- 6Despite positive sales growth, the company experienced increased costs due to inflationary pressures on labor, components, steel, and transportation, impacting margins.
- 7Operating cash flow decreased significantly to $203 million from $452 million in the prior year, primarily due to changes in working capital.